Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ultra-processed foods and mortality: analysis from the Prospective Urban and Rural Epidemiology study.
Dehghan M, Mente A, Rangarajan S, Mohan V, Swaminathan S, Avezum A, Lear SA, Rosengren A, Poirier P, Lanas F, Lopez-Jaramillo P, Soman B, Wang C, Orlandini A, Mohammadifard N, AlHabib KF, Chifamba J, Yusufali AH, Iqbal R, Khatib R, Yeates K, Puoane T, Altuntas Y, Co HU, Li S, Liu W, Zatońska K, Yusuf R, Ismail N, Miller V, Yusuf S; Prospective Urban Rural Epidemiology (PURE) study investigators. Dehghan M, et al. Among authors: altuntas y. Am J Clin Nutr. 2023 Jan;117(1):55-63. doi: 10.1016/j.ajcnut.2022.10.014. Epub 2022 Dec 20. Am J Clin Nutr. 2023. PMID: 36789944 Free article.
Prevalence of metabolic syndrome in patients with psoriasis.
Kutlu S, Ekmekci TR, Ucak S, Koslu A, Altuntas Y. Kutlu S, et al. Among authors: altuntas y. Indian J Dermatol Venereol Leprol. 2011 Mar-Apr;77(2):193-4. doi: 10.4103/0378-6323.77464. Indian J Dermatol Venereol Leprol. 2011. PMID: 21393953 Free article. No abstract available.
A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study).
Kanat M, Serin E, Tunckale A, Yildiz O, Sahin S, Bolayirli M, Arinc H, Dirican A, Karagoz Y, Altuntas Y, Celebi H, Oguz A. Kanat M, et al. Among authors: altuntas y. J Endocrinol Invest. 2009 Nov;32(10):852-6. doi: 10.1007/BF03345757. Epub 2009 Sep 11. J Endocrinol Invest. 2009. PMID: 19783896 Clinical Trial.
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, Chan M, Wolka AM, Boardman MK; DURATION-4 Study Group. Russell-Jones D, et al. Diabetes Care. 2012 Feb;35(2):252-8. doi: 10.2337/dc11-1107. Epub 2011 Dec 30. Diabetes Care. 2012. PMID: 22210563 Free PMC article. Clinical Trial.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. Pi-Sunyer X, et al. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. N Engl J Med. 2015. PMID: 26132939 Free article. Clinical Trial.
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK, Agner BFR, Altuntas Y, Grøn R, Halladin N, Klonoff DC, Tentolouris N, Jódar E. Billings LK, et al. Among authors: altuntas y. J Diabetes Sci Technol. 2021 May;15(3):636-645. doi: 10.1177/1932296820906888. Epub 2020 Feb 28. J Diabetes Sci Technol. 2021. PMID: 32107930 Free PMC article. Clinical Trial.
171 results